Financials Crystalvue Medical Corporation

Equities

6527

TW0006527005

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
82.2 TWD +0.61% Intraday chart for Crystalvue Medical Corporation +0.37% -5.19%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,012 1,681 1,186 1,144 1,241 2,190
Enterprise Value (EV) 1 664.7 1,164 771.4 988.1 1,096 1,942
P/E ratio 14.7 x 18.6 x 21.4 x 15 x 11 x 21.2 x
Yield 3.58% 3.25% 2.82% 4.05% 4.62% 2.39%
Capitalization / Revenue 1.67 x 2.54 x 2.35 x 1.59 x 1.56 x 2.66 x
EV / Revenue 1.1 x 1.76 x 1.53 x 1.37 x 1.38 x 2.36 x
EV / EBITDA 7.46 x 9.14 x 10.1 x 8.06 x 7.61 x 13.9 x
EV / FCF 11.9 x 17.5 x -17.2 x -4.36 x 146 x 16.8 x
FCF Yield 8.43% 5.71% -5.82% -23% 0.68% 5.96%
Price to Book 2.2 x 2.72 x 1.76 x 1.59 x 1.59 x 2.56 x
Nbr of stocks (in thousands) 22,376 22,491 25,057 25,057 25,057 25,264
Reference price 2 45.24 74.76 47.33 45.67 49.52 86.70
Announcement Date 4/25/19 3/31/20 3/3/21 3/1/22 2/24/23 3/1/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 606.3 661.1 504.4 721.6 795.5 824
EBITDA 1 89.04 127.4 76.31 122.6 143.9 139.5
EBIT 1 77.17 114.1 57.66 88.47 124.8 117.7
Operating Margin 12.73% 17.25% 11.43% 12.26% 15.69% 14.28%
Earnings before Tax (EBT) 1 80.34 111.7 62.96 109.2 142.4 119.7
Net income 1 69.89 91.08 56.62 77.24 115 103.4
Net margin 11.53% 13.78% 11.23% 10.7% 14.46% 12.55%
EPS 2 3.076 4.019 2.210 3.048 4.514 4.090
Free Cash Flow 1 56.01 66.41 -44.89 -226.8 7.495 115.7
FCF margin 9.24% 10.05% -8.9% -31.43% 0.94% 14.04%
FCF Conversion (EBITDA) 62.9% 52.14% - - 5.21% 82.9%
FCF Conversion (Net income) 80.15% 72.92% - - 6.52% 111.86%
Dividend per Share 2 1.619 2.429 1.333 1.848 2.286 2.070
Announcement Date 4/25/19 3/31/20 3/3/21 3/1/22 2/24/23 3/1/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2023 Q2 2023 Q3 2023 Q4
Net sales 1 327.7 - 220 189.4
EBITDA - - - -
EBIT 1 52.8 - 24.24 31.17
Operating Margin 16.11% - 11.02% 16.45%
Earnings before Tax (EBT) 1 47.99 - 29.14 25.97
Net income 1 42.56 34.47 23.31 18.39
Net margin 12.99% - 10.6% 9.71%
EPS 2 1.876 1.380 0.9300 0.7100
Dividend per Share - - - -
Announcement Date 3/29/20 8/14/23 11/14/23 3/1/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 348 518 415 156 145 248
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 56 66.4 -44.9 -227 7.49 116
ROE (net income / shareholders' equity) 15.8% 15.7% 8.23% 11.1% 15.4% 12.7%
ROA (Net income/ Total Assets) 8.26% 9.31% 4.03% 6.06% 7.99% 7.03%
Assets 1 846.6 978.5 1,404 1,275 1,439 1,470
Book Value Per Share 2 20.60 27.50 26.90 28.70 31.20 33.90
Cash Flow per Share 2 14.60 21.70 14.50 7.730 7.110 10.80
Capex 1 25.5 5.19 29.8 351 7.52 4.37
Capex / Sales 4.2% 0.79% 5.9% 48.66% 0.95% 0.53%
Announcement Date 4/25/19 3/31/20 3/3/21 3/1/22 2/24/23 3/1/24
1TWD in Million2TWD
Estimates
  1. Stock Market
  2. Equities
  3. 6527 Stock
  4. Financials Crystalvue Medical Corporation